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Abstract
Background: Irregularity in temperature regulation and control of breathing during the first few days are the
reasons for the abrupt deaths in preterm neonates, of which apnea in premature neonates constitutes the major
reason for these deaths. Methylxanthine’s (aminophylline and caffeine) are used in its treatment. Majority of the
hospitals follow a standard treatment regimen for both aminophylline and caffeine irrespective of preterm’s age
and body weight which leads to toxic or sub-therapeutic concentrations of the drug. Using Physiologically based
pharmacokinetic modelling (PBPK), various drug characteristics and its deportment can be studied. This helps
in predicting the Pharmacokinetic parameters of the drug which in turn aids in the individualization of dosing
regimen with respect to body weight and postnatal age.

Objectives: To develop a PBPK model for aminophylline and caffeine to aid in optimizing and individualizing
the dosage regimen with respect to body weight and postnatal age for the treatment of apnea in preterm neonates.

Methodology: Anonymized data of 108 and 61 preterm neonates with apnea from a previously reported study
were obtained for building an aminophylline and caffeine model respectively. The data was obtained from a
previous study conducted at NICU of Kasturba Hospital, Manipal University. Preterm neonates with less than
or equal to 34 weeks of gestational age and greater than 6 apneic episodes in 24 hrs were included in the study.
A standard treatment protocol of 5mg/kg loading dose and 2mg/ kg maintenance dose for every 8 hours and a
standard dosing regimen of 10mg/kg loading dose followed by 2.5mg/kg maintenance dose for every 24 hours
were used in this PBPK model development for aminophylline and caffeine respectively. Pk-Sim software
package was employed to build a predictive model. The predictions were compared to the reported data through
visual inspection and also by pharmacokinetic parameters comparison.

Results: Subgroup simulations provided evidence for the maturation of enzymes with the progression of time,
which in turn increases the clearance for both aminophylline and caffeine, which can be interpreted from the
visual predictive curve. The study also provides an evidence of decreased half-life of the drug in the body, where
t1/2 of 32.83 hrs and 29.87 hrs was reported in the Sub-groups PNA 1-6 and PNA > 6 respectevely in the
aminophylline group. Similarly, t1/2 of 67.04 hrs and 57.5 hrs was reported in the subgroups PNA 0-10 and PNA
> 10 respectively in the caffeine group. These results also provide an evidence for an improved renal function
with age in both the case groups (aminophylline and caffeine).

Conclusions: The study provides an evidence for the maturation of enzymes with the time and alteration of drug
characteristics like the volume of distribution and clearance concerning covariates body weight and postnatal
age. Hence it provides evidence in delivering optimized concentrations of the drug when dosing regimen is
individualized with respect to body weight and postnatal age.
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INTRODUCTION

1.1 APNEA

IN PRETERM NEONATES

Major neonatal deaths occur during the first week of life. Nearly one million newborns die within 24 hours of
their birth. Irregularity in temperature regulation and control of breathing during the first few days are reasons
for their abrupt deaths. Birth asphyxia (lack of breathing at birth), apnea of prematurity, infections and birth
defects are the major complications. Apnea of prematurity (AOP) occurs secondary to a physiological
immaturity of respiratory control (Barrington K et al, 1991; Zing Zhao et al, 2011). It is a developmental
disorder described as respiration cessation for more than 20 seconds or respiration cessation < 20 seconds
followed by bradycardia and cyanosis (Eric C Eichenwald, 2016). AOP involves diverse clinicopathological
events, Depression of cerebral hemodynamics which makes the ventral surface of medulla and the adjoining
areas of brainstem vulnerable to the inhibitory mechanisms like hypoxia, adenosine secretion, hypercapnia and
hyperthermia, leading to the apneic episodes in preterm infants. Apnea during infancy is frequent during active
or REM sleep compared to being infrequent during quiet sleep. There exists a complex relationship between
the central respiratory control and the central chemosensitive areas (Eldridge L F et al, 1983).

The decreased chemosensitive factors lead to an inadequate respiratory response (Darnall et al, 2006).
Reduced lung volumes leading to hypoventilation may also be an initial trigger. Gastroesophageal reflux being
difficult to diagnose in this age group due to the non-acidic nature could also be a suspected cause for apnea
(Varsha Bhatt et al, 2012). Although establishing the consequences of apnea of prematurity on
neurodevelopment in preterm remains a challenge, Regulation of the cerebral hemodynamics and respiratory
rate are few of the pivotal objectives to prevent premature death in preterm neonates with apnea.

1.2

MANAGEMENT OF AOP:

Apnea resolution and respiration rate control is the primary objective of avoiding preterm death. Continuous
positive airway pressure and nasal intermittent positive pressure ventilation, methylxanthine therapy and
doxapram therapy are the treatment strategies available.

Methylxanthine therapy:
The most commonly used agents for the management of AOP are Caffeine (1-3-7-trimethylxanthine) and
theophylline (1-3-dimethylxanthine) (Varsha Bhatt et al, 2012). The exact mechanism of action by which these
agents act in AOP remains poorly defined. Theophylline, an inhibitor of phosphodiesterase, and an adenosine
antagonist, operates by different mechanisms. Theophylline improves central respiratory enhancement by
antagonizing the role of adenosine, a core respiratory depressant and respiratory stimulant throughout the
periphery (Church M K et al, 1986). Phosphodiesterase inhibition of isoenzyme activity results in a breakdown
of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This leads to a

rise in cAMP and cGMP in the blood, which results in the relaxation of the airways (Trophy T J et al,1991;
Barnes P J et al, 1994). Theophylline also controls the release of catecholamines and modulates the calcium ion
flux (Ramirez G et al,1995; Kolbeck R C et al, 1988). Increased alveolar ventilation and carbon-dioxide
sensitivity are the physiological changes obtained following the administration of theophylline which provides
evidence of the respiratory centre's stimulation as a mechanism for AOP relief (Varsha Bhatt et al, 2012).
Caffeine being a non-adenosine antagonist modulates through neurotransmitters such as nor-adrenaline,
acetylcholine, dopamine, gamma-aminobutyric acid, and glutamine, increasing cAMP and cGMP leading to
bronchodilation. Caffeine stops apnea and initiates regular breathing by increasing the activation of the
peripheral chemoreceptors. In the immature lung, caffeine exhibits an anti-inflammatory action. Following
caffeine administration, the higher success rate for early nasal continuous positive airway pressure therapy
(nasal-CPAP) was recorded. Caffeine therapy also decreases ventilator-induced lung injury, which is critical in
the early neonatal phase. Early nasal CPAP therapy may not be effective in all infants during the prevalent
AOP. (Varsha Bhatt et al, Aug 2012).

1.3

METHYXANTHINES

1.3.1 Aminophylline
Aminophylline, a theophylline derivative, is a mixture of drugs containing 2:1 proportion of theophylline
and ethylenediamine. Theophylline once in the body acts as a blocker of adenosine receptor & histone
deacetylase activator which increases cAMP & cGMP causing bronchial smooth muscle dilation. The
standard treatment regimen of 5mg/kg of loading dose and 2mg/ kg of maintenance dose of aminophylline
is used for treating AOP (Amir MA et al, Aug 2014).
1.3.1.1 Absorption
When given orally aminophylline is immediately released and peak concentration is reached within 1 to 2
hrs. Its absorption is least affected in the presence of food. (Product Information: aminophylline IV injection
Hospira, 2004) (Product Information: aminophylline oral tablets, West- ward Pharmaceutical, Corp,
Eatontown, NJ, 2002).

1.3.1.2 Distribution
Once theophylline is released into systemic circulation 40% is protein-bound (primarily albumin). The volume
of distribution (Vd) ranges from 0.3L/kg to 0.7L/kg. Vd increases in preterms due to a decrease in plasma
protein binding which leads to an increase in the serum concentration of aminophylline leading to toxic
effects.

1.3.1.3 Metabolism

Metabolism by the liver in adults is a saturable process which primarily occurs through CYP1A2 mediated NDemethylation. Biotransformation of the aminophylline takes place through demethylation (1-methylxanthine
and 3-methylxanthine) and hydroxylation (1,3-dimethyluric acid). About 6% is metabolized to caffeine
through N-Methylation (Cheng et al, 1990; Denaro et al, 1990; Tang-Liu et al, 1982; Dahlqvist et al,).
Metabolic clearance is significantly higher compared to renal clearance (approximately 10% of the dose) in
adults, whereas in neonates due to the immaturity of metabolizing enzymes (CYP1A2, CYP2E1, CYP1A1)
50% of the drug is cleared unchanged through renal route (Ha et al., 1995; Bonati et al., 1981; Ogilvie). The
N-demethylation pathway is absent in neonates while the hydroxylation pathway role is significantly lacking.
The activity of these pathways increases gradually with enzyme maturation and reaches maximum levels by
the age of one. 3-Methylxanthine and Caffeine are the only pharmacologically active metabolites. 3Methylxanthine produces about one-tenth of theophylline's pharmacological activity. The half-life (t1/2) of
aminophylline in adults is around 8-9 hrs which substantially increases to 17-43 hrs in preterms with 3-15
days of postnatal age. Due to these differences in ADME of the drug in adults compared to preterms, dose
adjustment is needed. The therapeutic range of 5-20 mcg/ml serum concentration is proven to be safe and
effective in the treatment of AOP. Serum concentration exceeding greater than 20 mcg/ml produces toxic
effects. (Product Information: aminophylline IV injection Hospira, 2004) (Product Information:
aminophylline oral tablets, West-ward Pharmaceutical, Corp, Eatontown, NJ, 2002).

Fig 1. Metabolism of Aminophylline

1.3.1.4 Excretion

In neonates, 50 percent of the aminophylline dose is excreted unchanged by urine, but only 10 percent is
excreted unchanged in the urine after about three months of age and the rest is metabolized into 1methylxanthine, 3-methylxanthine, 1,3-dimethyluric acid, 1,3,7-trimethyluric acid and caffeine. Since there is
minimal evidence regarding the accumulation at clinically significant levels of active metabolites (i.e. caffeine,
3-methylxanthine) even in the end-stage renal disease. Dosage adjustment is not required in adults and children
older than 3 years for renal insufficiency. In comparison, close consideration is required to reduce the dose and
track serum theophylline concentrations in neonates under 3 years of age with decreased renal function. This is
because a large fraction of the theophylline dose is excreted in the urine as unchanged theophylline and caffeine
(Product Information: aminophylline IV injection Hospira, 2004) (Product Information: aminophylline oral
tablets, West-ward Pharmaceutical, Corp, Eatontown, NJ, 2002).

1.3.2 Caffeine:

Caffeine Citrate is the salt form of caffeine base belonging to the class of methylxanthines. This is a known
competitive inhibitor of the phosphodiesterase enzyme which is responsible for the inactivation of the
cyclic adenosine monophosphate (cAMP).

Mechanism of action involved in the treatment of apnea of prematurity:

According to Anari et.al, 2017 the mechanism is not well established because the molecular and cellular
targets involved in the CNS are not clearly known but it is hypothesized to be involved in the
1. Simulation of the respiratory core by adenosine receptor's competitive antagonism (Fred- holm,1995).
Increases in minute ventilation by increasing central CO2 sensitivity and improving function of the
respiratory muscles (Abhu shaweesh et al,2011).
2. Decreased diaphragmatic failure
3. Increased metabolic rate and increased oxygen consumption.

1.3.2.1 Pediatric Dosing in The Treatment of Apnea of Prematurity:

1. FDA Labeled Dosage for Apnea of Prematurity:
Loading Dose: 20mg/kg/IV over 30min given as a single dose with a syringe infusion pump. Maintenance
Dose: 5mg/kg/IV over 10min given with a single infusion pump every 24 hours (start after 24hrs of the
loading dose)

2. Off-label Dosage for Apnea of Prematurity:
Loading Dose: 20mg/kg-25mg/kg IV/PO over 30minutes every 24hours.
Maintenance Dose: 5mg/kg – 10mg/kg IV/PO over 30minutes every 24 hours (start 24hrs after the loading
dose).
High Dose Maintenance: 10mg/kg – 20mg/kg/day IV/PO every 24 hours (start 24hrs after the loading dose).
According to the product information IV/PO, Sun pharma Ltd. “The dose of caffeine citrate is twice the
dose of the caffeine base.” For example, 10mg of caffeine citrate is equal to the 5mg of caffeine base.

1.3.2.2 Pharmacokinetics:

The pharmacokinetic profile of the caffeine is very well described in the product information IV/ PO, Sun
pharma Ltd. According to this product information label the absorption, distribution, metabolism and
excretion of the caffeine citrate is as follows

Absorption:

Caffeine is well absorbed via oral, rectal and percutaneous routes of administration. IV route of
administration is preferred in the treatment of apnea of prematurity in infants and the bioavailability of
caffeine base is half the concentration of caffeine citrate.

Distribution:

The unbound plasma concentration of caffeine in neonates is 70%. Caffeine being a hydrophilic drug it
distributed widely across the tissues. The volume of distribution of caffeine in preterm neonates is found to
be 0.8-0.9L/Kg. Scott NR et.al,1989 described a decrease in volume of distribution in chronic liver disease
patients.

Metabolism:

In adult’s caffeine is extensively metabolized by the liver. The enzymes involved in the metabolism of
caffeine are CYP1A1, CYP1A2, CYP3A4, CYPD6 and CYP2E1. In neonates the hepatic enzymes are not
well developed, and the metabolites are paraxanthine, theobromine, theophylline and trimethyl uric acid.

Excretion:

The average t1/2 of caffeine is expected to be between 52 to 96 hours in neonates as per De Caraolis et.al,
1991. The adult half-life 5-6 hrs is achieved by the age of 9 months. The 86% of the parent compound is
excreted unchanged in urine in 6 days.

1.3.2.3 Adverse Drug Reactions:

Common
1. Psychiatric: Irritability
2. Other: Feeding problem symptom

Serious
1. Endocrine metabolic: Acidosis (rare), Hyperglycemia, Hypoglycemia, Impaired wound healing (rare)
2. Gastrointestinal: Gastritis (rare), Gastrointestinal hemorrhage (rare)
3. Hematologic: Disseminated intravascular coagulation (rare), Hemorrhage.
4. Neurologic: Central nervous system stimulation, Cerebral hemorrhage (rare)
5. Ophthalmic: Retinopathy of prematurity (rare)
6. Renal: Renal failure (rare)
7. Respiratory: Dyspnea (rare), Pulmonary edema (rare)
8. Other: Sepsis (rare)

1.3.2.4 ADRs of Caffeine Citrate associated with the AOP Treatment:

1. Vascular perfusion of the organs or tissues decreased: palpitations, flushing, arrhythmias, tachycardia,
prolonged QRS interval, myocardial infarction and reduced blood flow in neonates with caffeine use.
(Somani & Gupta, 1988; Palmer et al, 1995; Donner- stein et al, 1998)

2. Dermatologic Effects: Rash, dry skin, and skin breakdown were recorded in 8.7 percent, 2.2 percent, and
2..2percent, respectively, of infants in a randomized trial (n=85) (Prod Info Cafcit (R), 2000).

3. Endocrine/Metabolic Effects: Acidosis and Abnormal Healing were each reported in 2.2% of infants
during the treatment. (Prod Info Cafcit (R), 2000).

4. Gastrointestinal Effects: In a randomized trial (n=85), there were records of feeding aversion,
necrotizing enterocolitis, gastritis, and gastrointestinal hemorrhage in 8.7%, 4.3%, 2.2%, and 2.2%,

respectively. (Prod Info Cafcit (R), 2000).

5. Hematologic and neurological Effects: Hemorrhage and Cerebral Hemorrhage was reported in 2.2% of
infants (Prod Info Cafcit (R), 2000).

6. Ophthalmic Effects: Retinopathy of prematurity was reported in 2.2% of (Prod Info Cafcit (R), 2000).

7: Renal Effects: Kidney Failure was reported in 2.2% of infants (Prod Info Cafcit (R), 2000).

8. Respiratory Effects: Dyspnea and Lung Edema were each reported in 2.2% of infants (Prod Info Cafcit
(R), 2000). Hyperventilation and Tachypnea have been associated with caffeine use (usually in doses
greater than 250 mg/day).

9. Oher: Sepsis and Accidental Injury were reported in 4.3% and 2.2% of infants (Prod Info Cafcit (R), 2000).

10. Withdrawal symptoms in neonates: Chronic ingestion of excessive amounts (2-18 cups ap- proximately
200-1800mg) of caffeine throughout pregnancy has been associated with the withdrawal symptoms in
newborn infants. The primary withdrawal symptoms observed were tremulousness, irritability, and nonbilious vomiting. Maternal consumption of as low as 200 to 360 mg caffeine daily (2 to 3 cups of coffee per
day) produced vomiting and irritability in 1 neonate. All these symptoms resolved within 7 days with no treatment.

PHYSIOLOGICALLY BASED
PHARMACOKINETIC
MODELLING

2.1

PBPK Models and building blocks:

Definition:
It is a mathematical modeling technique for human and other animal species to predict the absorption,
distribution, metabolism and excretion of synthetic or natural chemical substances.

Types of PBPK Model:
1. Whole Body PBPK Model:

Peter S A et.al defined the whole body PBPK model as a schematic representation of the organs that are
associated with the absorption, distribution, metabolism and excretion of the drug due to their physiological/
pharmacological function/their function. Considers every organ as a different compartment with organ
specific drug input and output rates.

2. Partial PBPK Model:

In this type of PBPK Model the highly perfused tissues or organs are grouped as one compartment and the
blood flow to all these organs grouped is assumed to be same. According to L Kuepfer et.al the PBPK
model is typically made up of four building blocks. These building blocks serve as the inputs to the model
and the model predictions are made based on these input parameters.

Organism Parameters:
These properties depend on the species and population specific. Each organ is represented based on the
prior knowledge of the anatomy and physiology of the organism of interest. This section includes organ
volumes, organ composition, blood flows, surface areas, and expression levels. For an individual
simulation, the parameters should be based on the parameters of the subject/ participant from the clinical
study. To build a population model first you have to build an individual representing the mean of the
population and create the required number of the virtual individuals based on the range of the clinical
population.

Drug Properties:
Includes both physiochemical properties and the biological properties of the specific drug. The
physiochemical properties such as lipophilicity, solubility, PKa of the drug are also called as drug specific

parameters as they solely depend on the specific compound. Whereas the drug biologic properties such as
fraction of unbound drug and tissue plasma partition coefficient depends on the organism’s parameters as
well along with the drug parameters. Along with both physiochemical and biological properties a detailed
input on the metabolizing enzymes, transport proteins and the clearance processes such as renal, biliary and
hepatic concentrations is also necessary.

Formulation:
This has a very big role in the design of the dosage form for a new chemical entity in the invitro
bioavailability studies. During invitro in vivo correlation (IVIVC) which is one of the applications of the
PBPK modelling the input of the type of formulation and the rate at which the drug is absorbed from the oral
formulation has a role in the invitro bioavailability testing.

In the PK-SIM there are four different options available under the oral formation based on the release of
the drug from the formulation they are dissolved, Weibull, lint80, particle dissolution, table, first order and
zero order. This input is very important in the simulation of absorption models.

Administration Protocol:
This section of the building blocks mainly comprises of three main parts
1. Route of administration.
2. Amount of the dose administered.
3. In case of the multiple dosing the dosing schedule.

The model administration protocol given as input will be similar to that of the clinical study from which
the observed concentration will be used for the model validation. In the PK-SIM there are two different
types of the protocol that is the simple and advanced protocol. The simple protocol is usually used when
giving an input for the single dose administration whereas the advanced section is used when the multiple
doses are administered.

Building blocks for
PBPK modelling

Organism
Parameters

Age, Bodyweight,
PNA, GA

Administration
protocol

Loading dose,
Maintainence
dose

Formulation

Applicable for oral
dosage form only

Drug properties

Lipophilicity,
Fraction unbound,
Pka, Solubility

Fig 2. Building Blocks of the PBPK Modelling

Applications of PBPK models:
1. Useful in the prediction of concentration profiles in the special populations (Pediatric extrapolations,
Special Populations, Disease Populations.)
2. Evaluation of Drug-Drug interactions.
3. Cross Species extrapolation.
4. In-vitro- In-vivo Correlation (IVIVC).

2.2 Significance of The Pediatric PBPK Model:
In pediatrics a traditional pharmacokinetic study is very tough to perform due to various factors such as the
number of samples to be collected, the blood volume (Howie SR et.al), requirement of the same protocol ,
dosing schedule and sample collection at the regular intervals and various ethical concerns (Roth-Cline M
et.al; Barker CIS, et.al). Hence Population Pharmacokinetic approach is employed in order overcome the
major limitations of the traditional PK studies which uses sparse sampling technique. The Pop PK studies do
not include the developmental differences in the pediatric group which is one of the major challenges
determining the dosage adjustments in the pediatrics. The PBPK models which include the anatomy and
physiology of the subject in order to determine the concentration in the neonates have gained a significant
importance in the pediatric dosage adjustments (Penkov D et.al). Apart from this they can also be used to
determine the first dose in pediatrics as they facilitate cross species extrapolation. The regulatory authorities
incorporated the guidelines for the model development and qualification (Committee for Medicinal Products
for Human Use (CHMP) et.al)

2.3 Software’s Available for The PBPK Modeling:
The development of commercial platforms integrating physiological databases and the implementation of
PBPK modeling approaches facilitates the construction of PBPK models. These software’s differ from in
various approaches made to facilitate using friendly but at the core they all include physiological databases
that are combined with the compound. Various software’s include GastroPlus (Simulations Plus, Lancaster,
PA), SimCyp (SimCyp, Sheffield, UK), and PK- Sim and MoBi (Bayer Technology Services, Leverkusen,
Germany). PK-SIM is an open source from open systems pharmacology. These commercial PBPK
modeling systems have the physiology of predefined organisms and populations with a standardized model
framework.

2.4 PK-Sim for Physiologically Based Pharmacokinetic Modelling:
Pk-Sim and MoBi are part of Open Systems Pharmacology, an open-source tool designed to perform efficient
multi-scale modelling and simulations based on modular concepts. These software tools make use of building
blocks where Pk-Sim works on the whole-body concept, the focus of its counterpart MoBi lies at the
molecular level. PK-Sim provides access to all the relevant anatomical and physiological parameters from
the integrated database for humans and common laboratory animals like mouse, rat, pig and monkey. It also
provides different Physiologically Based Pharmacokinetic (PBPK) calculation and parameterization
methods. Relevant processes, such as the distribution of the drugs through blood flow as well as specific
active processes are automatically taken into consideration by PK-Sim. It provides various model structures
to opt for such as, to explore differences for small molecular compounds and large molecular compounds
etc. These building blocks include Individuals, Populations, Compounds, Formulations, Administration
Protocols, Events, and Observed Data. Pk-Sim further can be used to compare two individual simulations
and derive results out of it (Stephanie Laer, 3rd March,2011).

AMINOPHYLLINE

3.1

Methodology:

3.1.1 Material and Methods

Anonymized data of 108 preterm neonates with apnea were obtained from the previous study conducted at
NICU of Kasturba Hospital, Manipal University. Preterm neonates with less than or equal to 34 weeks of
gestational age and greater than 6 apneic episodes in 24 hrs were included in the study (Shivakumar M et al.).
Dosing began as early as from day 2 with follow up dosing every 8 hrs. All the subjects were prescribed doses
ranging from 1.2 - 3mg/kg every 8hrs following a loading dose ranging from 4 - 10mg/kg. A standard
treatment protocol of 5mg/kg loading dose and 2mg/ kg maintenance dose for every 8 hours is used in this
PBPK model development. The plasma and urine amount of theophylline were calculated from the model
using Area under curve and individualized dose.

Clearance (Cl) = Dose / AUC

Need for study:
Aminophylline is recommended as a prophylactic treatment for AOP. The major concern is the higher
chance of toxicity or achieving subtherapeutic levels of the drug due to the immaturity of metabolizing
enzymes and clearance of the drug and its metabolites from the body. By predicting the ADME of a drug
in preterms dose can be adjusted accordingly.

3.1.2 Model Building

Individual and Population building blocks.

PBPK models were built using the building blocks from PK-Sim. A mean individual representing the
unabridged population (whole population) was created using the Individual block. This mean individual is
used to produce a set of 100 and 50 virtual individuals for building a population representing the unabridged
population and subgroup populations which were divided based on covariates weight and PNA, respectively.
The Population were built around the range of demographics represented in Table 1. All these functions were
performed using the population building block from PK-Sim. Table 1 represents the demographic inputs used
in building an individual and unabridged population around the mean individual.

Table 1. Patient Demographics Data
Number of patients

108

Body weight (Kgs)

1.123 (0.56 - 2.34)*

Postnatal age (Days)

6.85 (2 - 23)*

Height (cm)

35.84 (28.31 - 43.41)*

Gestational age (weeks)

30 (26 - 34)*
*Mean (Range)

Compound Parameters:

Aminophylline is a derivative of theophylline which is combined with ethylenediamine to enhance the
solubility. Upon conversion to theophylline, 40% of the agent is primarily bound to albumin. Aminophylline is
primarily metabolized in the liver and follows mixed order kinetics. A fraction of parent compounds and
metabolites are thought to be eliminated through urine. CYP450 iso-enzymes (CYP1A2, CYP2E1, CYP1A1)
play an important role in its metabolism. CYP1A2 catalyzes the metabolism of theophylline to demethylated
products. Hydroxylation occurs at a rapid rate with the substantial activity of both CYP1A2 and CYP2E1.
CYP1A2 having higher affinity is predominant at lower doses and is readily saturable compared to CYP2E1.
CYP1A1 manifests some activity in the formation of 1-Methylxanthine (Ginsberg et al, Aug 2010). Expression
of CYP genes in the recombinant systems of human B-lymphoblastoid cell lines was used to study the various
activities of the CYP enzymes towards these xanthine substrates. Biotransformation of these CYP enzymes was
evaluated by Ha et al (1995). Michaelis-Menten Constants for these CYP enzymes which demonstrate their
activity on the metabolism of theophylline are shown in Table 3.

Table 2. Compound Parameters
Parameter:

Input values:

Reference:

LogP

-0.02

Drugbank

Fraction Unbound

0.6 Log Units

Drugbank

Molecular Weight

180.1 g/mol

Drugbank

Solubility at pH 7

7360 mg/L

Drugbank

Table 3. Theophylline metabolism to 1-MX, 3-MX and 1,3-U (Ginsberg et al, Aug 2010)
1-Methylxanthine (1-MX)

3-Methylxanthine (3-MX)

1,3-Dimethyluric acid
(1,3U)

CYP isoform

Vmax

Km

Vmax

Km

Vmax

Km

CYP 1A1

0.22

0.31

NIL

NIL

NIL

NIL

CYP 1A2

6

0.38

2.44

1.09

7.32

0.23

CYP 2E1

NIL

NIL

NIL

NIL

68.67

15.3

Vmax in µmol metabolite formed/min/µmol CYP, Km in mmol/L

Administration protocol:

A standard protocol of 5mg/kg loading dose of theophylline infused over 30 min and 2mg/kg maintenance
dose of theophylline infused over 10 minutes was used for constructing the model. Dose adjustments from
aminophylline to theophylline were made using the salt factor of 0.8 to have an effective measure of serum
theophylline levels (Product Information: aminophylline IV injection, aminophylline IV injection. Hospira,
Inc, Lake Forest, IL, 2004.) (Product Information: aminophylline oral tablets, aminophylline oral tablets.
West-ward Pharmaceutical, Corp, Eaton- town, NJ, 2002).

Subgroup Population:

As stated in the section previously, subgroup populations were built around the mean individual. 50 virtual
individuals in each population were generated around the range of demographic data represented in Table 4
and 5 respectively. Subgroups were created for the covariates PNA and weight. Table 4 and 5 represent the
demographic inputs used in constructing the subgroup population.

Table 4. Postnatal age-based Subgroup Demographic Data
Group 1

Group 2

Number of patients

57

51

Weight (Kgs)

1.22 (0.65 - 2.34)*

1.02 (0.56 - 1.76)*

Postnatal age (Days)

4.89 (2 - 6)*

9.04 (7 - 23)*

Height (cms)

36,.24 (28.75 - 41.15)*

35. 28 (28.31 - 43.41)*

Gestational age (Weeks)

30.22 (26 - 34)*

29.82 (26 - 34)*

*Mean (Range)

Table 5. Weight based Subgroup Demographic Data [Mean (Range)]
Group 1

Group 2

Group 3

Number of patients

44

50

14

Weight (Kgs)

0.854 (0.56 - 0.99)*

1.17 (1 - 1.49)*

1.8 (1.59 - 2.34)*

Postnatal age (Days)

7.36 (3-23)*

6.76 (2 - 22)*

5.57 (4 -10)*

Height (cms)

35.41 (29.96 - 40.24)*

36.03 (28.31 - 43.41)*

36.45 (33.53 - 39.8)*

28.84 (26 - 34)*

30.54 (26 - 34)*

32 (26 - 34)*

Gestational age
(Weeks)

*Mean(Range)

Simulation:

The Model was simulated for the unabridged population of 100 virtual individuals with the predetermined
standard protocol of 5mg/kg loading dose and 2mg/kg maintenance dose with a dosing interval of 8 hrs for
424 hrs. Clearance post-loading dose was compared to the clearance post final dose. The clearance was
calculated using the obtained PK parameters from the simulation. The predicted time-concentration profile
showed an increase in clearance with time due to the maturation of liver enzymes with age.

Predicted peripheral venous blood-plasma concentrations of theophylline (Arithmetic mean)
Predicted peripheral venous blood-plasma concentrations of theophylline (Arithmetic standard deviation)
•

Observed concentrations

Fig 3. Time vs Concentration for the unabridged population

Further simulations were performed for the subgroups with 50 virtual individuals in each sub-group. The
preterms were sub-grouped into 3 categories based on weight (less than 1 kg, 1-1.5 kg, greater 1.5 kg) and
the models were simulated. Results are represented in the figures below (Fig 3, Fig 4, Fig 5).

Predicted peripheral venous blood-plasma concentrations of theophylline (Arithmetic mean)
Predicted peripheral venous blood-plasma concentrations of theophylline (Arithmetic standard deviation)
•

Observed concentrations

Fig 4. Time vs Concentration profile for Preterms weighing less than 1 kg

Predicted peripheral venous blood-plasma concentrations of theophylline (Arithmetic mean)
Predicted peripheral venous blood-plasma concentrations of theophylline (Arithmetic standard deviation)
•

Observed concentrations

Fig 5. Time vs Concentration profile for Preterms weighing 1-1.5 Kg

Predicted peripheral venous blood-plasma concentrations of theophylline (Arithmetic mean)
Predicted peripheral venous blood-plasma concentrations of theophylline (Arithmetic standard deviation)
•

Observed concentrations

Fig 6. Time vs Concentration profile for Preterms weighing greater than 1.5 kg

The preterms were sub-grouped into 2 PNA categories (ranging from 1 to 6 days and PNA greater than 6
days). The models were simulated, and the results are represented in the figures below (Fig 6, Fig 7)

Predicted peripheral venous blood-plasma concentrations of theophylline (Arithmetic mean)
Predicted peripheral venous blood-plasma concentrations of theophylline (Arithmetic standard deviation)
•

Observed concentrations

Fig 7. Time vs Concentration profile for preterms with postnatal age ranging from 1 to 6 days

Predicted peripheral venous blood plasma-concentrations of theophylline (Arithmetic mean)
Predicted peripheral venous blood plasma-concentrations of theophylline (Arithmetic standard deviation)
•

Observed concentrations

Fig 8. Time vs Concentration profile for preterm with postnatal age greater than 6 days

Clearance calculation:

Clearance (CL) post-loading dose and clearance post last maintenance dose was calculated using dose,
individualized to each preterm of the virtual population and the AUCinf_t1 and AUCinf_tLast. The obtained
CL was multiplied by 60 to obtain CL in L/hr.
Clearance post LD = Dose (mg)/ AUCinf_t1 (μg*min/ml) Clearance
post last MD = Dose (mg)/ AUCinf_tLast (μg*min/ml)

3.1.3 Results
The study was conducted from the previously obtained data from 108 preterms. Demographics of these
patients (Table 1, 4 and 5) were used to build a virtual population representing an unabridged population and
subgroup populations. The primary measure of outcome was clearance. Clearance post LD in unabridged
population was 0.026 L/hr which substantially increased to 0.055 L/hr post last maintenance dose. PNA

based Subgroup simulations provide a shred of evidence for the maturation of enzymes with the progression
of time which in turn increases the clearance. Weight-based subgroup simulations also provide a similar
trend of increase in clearance with time. There is also increase of clearance with the increase in bodyweight
post-loading dose (CL post LD of BWT 0-1 < BWT 1-1.5 < BWT greater than 1.5) but this reverts with the
progression of time (CL post last MD of BWT 0-1 > BWT 1-1.5 > BWT greater than 1.5). This provides
evidence for the alteration in distribution characteristics with regards to body weight and progressing time
and this results in altered standard dosing patterns which leads to increased plasma concentration in preterms
with BWT 0-1 and sub-therapeutic levels of plasma concentration in preterms with BWT greater than 1.5
post LD. CL in various populations is represented in Table 6.

The Pharmacokinetic parameters representing the mean individual from each population are represented in
Table 7.

Table 6. Clearance (CL)
CL Post LD

CL Post Last MD

Unabridged population

0.026388188

0.054788956

BWT 0-1 (Kg)

0.016237354

0.090393858

BWT 1-1.5 (Kg)

0.019849332

0.058491951

BWT greater than 1.5 (Kg)

0.023381645

0.033613176

PNA 1-6 (Days)

0.024577978

0.0597144

PNA greater than 6 (days)

0.027330422

0.092659935

Clearance in L/hr

Table 7. Pharmacokinetic Parameter output representing mean individual from each population

Unabridged
Population
BWT 0-1 (Kg)
BWT 1-1.5
(Kg)
BWT greater
than 1.5 (Kg)
PNA 1-6
(Days)
PNA greater
than 6 (Days)

AUC_inf_t1

AUC_inf_tLast

(µg*min/ml)

(µg*min/ml)

14492.29581

Cmax (µg/ml)

MRT (hr)

Half-Life

31585.54898

15.276082

35.1

31.71

13249.78591

25272.95393

14.35397

31.11

29.44

15581.72071

33089.07601

15.396749

37.61

33.74

18059.42664

46795.66396

18.323374

44.69

38.37

14915.55782

33073.24522

16.016293

35.36

32.83

13655.69168

23777.47738

13.541719

32.97

29.87

•

AUC_inf_t1 - AUC from the first data point extrapolated to infinity

•

AUC_inf_tLast - AUC from the time of last dose extrapolated to infinity

•

Cmax - Maximum concentration

•

MRT – Mean Residence Time of the drug molecule

•

Half-Life – Half-life time associated with terminal slope

3.1.4 Discussion

Preterm births lead to various complications, one of it includes apnea of prematurity. Methylxanthine therapy
is the most used way of management and this hurdles in achieving an absolute therapeutic concentration
necessary with the standard dosing regimen. The benefits of methylxanthine treatment for premature apnea
outweigh potential short-term risks. Postnatal methylxanthine therapy may lead to altered behavioral and
respiratory control in offspring’s (Tracey H Reilly, Pediatric Theophylline Toxicity, Medscape).
Aminophylline / Theophylline, due to narrow therapeutic range, when prescribed, due to immaturity in the
development of the physiological system in the preterms the prescribed drugs may cause toxicity or end up
with subtherapeutic concentrations. Hence individualized dosing adjustment is necessary. In the current study,
a standard dosing protocol of 5 mg/kg loading dose and 2 mg/kg maintenance dose with a dosing interval of
8 hrs was compared in preterms with different body weights and its effect with the progression of age. Serum
concentration ranging from 15-20 mcg/ ml is considered effective and anything greater than 20mcg/ml leads
to toxicity. The predicted mean concentration for the unabridged population was found to be 15.27 mcg/ml.
Which when compared to the subgroups based on weight, predicted concentrations were in stoop with the
actual concentrations only in the averaged weighted preterms (BWT 1-1.5) were predicted mean concentration
was found to be 15.4 mcg/ml (Fig 4, Table 7). The predicted mean theophylline concentration in preterms
weighing less than 1 kg was found to be 14.4 mcg/ml (Table 7) which when compared with the concentrations
from the actual patient data, it was found that the patients were having serum concentrations greater than the
predicted range (Fig 3). This reverts with the preterms weighing greater than 1.5 kg where the actual
concentrations were below the predicted concentrations (Fig 5). This can provide an evidence for the
relationship between alteration of distribution and bodyweight. With maturation the relative amount of body
water and fat levels change. When measured as a percentage of body weight, the total body water is decreased
from 80 to 60% from birth to 1 year. (Hong Lu and Sara R, 2014). Similarly, when compared the subgroups
based on PNA, clearance post-loading dose was greater in subgroup PNA > 6 days when compared to PNA
1-6 days (Table 6). With the progression of time, after the last maintenance dose i.e. after 482 hrs the
clearance was found to be in the same fashion with the mean clearance of 0.06 L/hr in subgroup PNA 1-6
days and 0.09 L/hr in subgroup PNA > 6 days. These results suggest lower maturation of hepatic enzymes
and renal function which lead to lower clearance and increased bioavailability of the compound. The
maturation of CYP1A2 begins from day 8, which reaches the adult levels by the age of 12 to 18 months (Hong
Lu and Sara R, 2014). This provides evidence for the greater clearance in subgroup PNA > 6 days compared
to subgroup PNA 1-6 days. Similarly, the maturation of CYP2E1 begins from the less than 24 hrs which
contributes to the majority of metabolism of theophylline till the third month (Hong Lu and Sara R, 2014).
The significant findings of the present developed model were that body weight and PNA has a notable
influence on clearance (Fukuda M.S, et all November 2005). In a study, the effect of age on preterm
metabolism of theophylline (Grygiel J.J and Brikett D.J, 1980) it was stated that adults and children have a
dual pathway to metabolize theophylline which is N-demethylation and 8 - hydroxylation which is not
developed in preterm neonates up to 40 weeks of gestation. In the current study, there is an increase in

clearance with post-natal age (Table 6) due to maturation of liver enzymes (Aranda et al, 1976). Theophylline
is 60 % bound to albumin in adults and about 53 to 65 % theophylline is bound reversibly bound to circulating
plasma proteins in adults but due to lack of this plasma protein in neonates the free drug availability is elevated
in the blood leading to increased bioavailability which in turn increases the half-life by almost 8 fold and
reversible binding to circulating plasma proteins is reduced to an average of 36% in neonates which leads to
toxicity and adverse effects (Jacob V et al,1976).

CAFFEINE

4.1

Methodology

4.1.1 Materials and Methods:

Anonymized data of 61 preterm neonates with apnea were obtained from the previous study conducted at
NICU of Kasturba Hospital, Manipal University. Though the study was done based on the standard dosage
regimen that is 10mg/kg of Caffeine base as a loading dose followed by 2.5mg/kg of caffeine base as
maintenance dose. But the clinically unresponsive subjects were titrated to a dose of 7.5mg/kg. To maintain
dosage uniformity the subjects deviated from the exact standard dose were excluded.

4.1.2 Model Building

Organism Parameters:

The modeling was done using PK-SIM Software. We created an individual representing the whole
population and 100 virtual individuals were simulated around the mean individual using the range of the
population parameters. The mean and the range values used for creating the mean individual and Population
are listed below.

S.No

Parameter

Mean

Range

1.

Body weight

1.22 Kg

0.56 – 2.01 Kg

2.

Height

36.33 Cm

27 - 43 Cm

3.

Post Natal Age

3.29 days

1 - 18 Days

4.

Body Mass Index

9.24

------

5.

Gestational Age

30.14

26-35

Table 8. Organism Parameters Used for The Population Model of Caffeine.

Compound Parameters:

In the compound parameter section, all the processes involved in the absorption, distribution, metabolism and
excretion of the drug. The base line compound parameters for caffeine are as follows:

S.No

Parameter

Value With Units

Reference

1.

Lipophilicity

-0.07 Log units

PubChem

2.

Fraction Unbound

70%

PubChem

3.

Solubility

21600mg/L

PubChem

4.

Pka (Base)

0.80

PubChem

Table 9. Drug Parameters Used for The Population Model of Caffeine.

The metabolism of caffeine is a saturable process and it follows mixed order kinetics with an initial zero
order followed by a first order process. Caffeine is mainly metabolized via four hepatic enzymes namely
CYP1A2, CYP2E1, CYP3A4, CYP1A1. The major metabolites of caffeine are Paraxanthine, Theobromine,
Theophylline and Trimethyl uric acid. The Vmax and Km values were taken from the literature of the invitro
recombinant CYP enzyme system (Data of Ha et al., 1995, 1996).

S.No

1.

2.

Enzyme

CYP1A1

Metabolite

Vmax (mol/min/
mol rem.enzyme)

Km(mmol/
l)

Paraxanthine

0.05

0.59

Theobromine

0.01

0.41

Theophylline

0.06

0.26

Paraxanthine

0.51

0.19

Theobromine

0.05

0.16

Theophylline

0.02

0.25

Trimethyl Uric Acid

0.03

0.27

CYP1A2

3.

CYP3A4

Trimethyl Uric Acid

0.46

46.0

4.

CYP2E1

Theobromine

0.0008

1.44

Theophylline

0.0006

0.84

Trimethyl Uric Acid

0.05

1.04

Paraxanthine

0.56

11.0

Theobromine

0.28

15.90

Theophylline

0.63

12.50

Trimethyl Uric Acid

0.21

9.13

5.

CYP2D6

Table 10. Vmax And Km Values for The Hepatic Clearance Used for The Population Model of Caffeine.

Administration Protocol:

The Administration protocol for the caffeine is as followed as per the clinical study first a loading dose of
10mg/kg is given followed by a maintenance dose of 2.5mg/kg .If there was no response the dose was
increased to 7mg/kg. The subjects which required higher doses any alteration in the dosing regimen were
excluded. The clinically observed concentration versus time was added to the observed data tab and pulled
over the predicted concentration with standard deviation versus time.

Subgroup Analysis:

The population was divided into three subgroups based on the weight. To build a model based on the
subgroups the compound parameters and the administration protocol were cloned as per the population
model and the group specific mean and range of the organism parameters are given as an input.

The subgroups based on the weight are as follows.

S.No

Name

Weight Range (Kg)

1

Group 1

0.5-1.0

2

Group 2

1.0-1.5

3

Group 3

>1.5

Table 11. Classification of Subgroups Based on Body Weight

Input values of range and mean of the sub populations used to create the subgroup organism
parameters are as follows:

Parameter

Group 1

Group 2

Group 3

Mean

Range

Mean

Range

Mean

Range

Body Weight
(Kg)

0.825

0.56-0.99

1.24

1.01-1.5

1.7

1.6-2.01

Gestational
Age (Months)

29

26-32

30.66

27-35

32.14

31-33

Post Natal
Age (Days)

4.09

1-14

2.96

1-18

3.285

2-6

Height (Cm)

33.18

27-38

36.88

30-41

39.14

34-43

Table 12. Mean and range values of Body weight sub population

The subgroups based on PNA are as follows:

S.No

Name

PNA range (days)

1

Group 1

0-10 days

2

Group 2

>10 days

Table 13. Classification of Subgroups Based On PNA

Parameter

Group 1

Group 2

Mean

Range

Mean

Range

Body Weight
(Kg)

1.2675

0.615-2.005

1.214

0.56-1.8

Gestational Age
(Months)

30.5375

27-33

30.86

27-35

Post Natal Age
(Days)

6.6375

2-10

14.74

11-37

Height (Cm)

36.325

28-43

36.71

27-43

Table 14. Mean and range values of PNA subgroups

4.1.3 Results

From the available dataset, the PBPK model for caffeine population was generated and the results are presented
below as figures and tables. The figure below shows the time vs conc profile for the whole caffeine population

Predicted peripheral venous blood-plasma concentrations of caffeine (Arithmetic mean)
Predicted peripheral venous blood-plasma concentrations of caffeine (Arithmetic standard deviation)

•

Observed concentrations

Fig 9. Time Vs Concentration profile- whole preterm population

PARAMTER

VALUE

AUC_inf_tD1 [µmol*min/l]

465013.44

AUC_inf_tD1_norm [µg*min/l]

9.03E+12

AUC_inf_tDLast [µmol*min/l]

482007.66

AUC_inf_tDLast_norm [µg*min/l]

3.744E+13

AUC_tD1-tD2 [µmol*min/l]

101948.83

AUC_tD1-tD2_norm [µg*min/l]

1.98E+12

AUC_tDlast-1_tDlast [µmol*min/l]

94410.422

AUC_tDlast-1_tDlast_norm [µg*min/l]

7.333E+12

C_max [µmol/l]

94.501282

C_max_tD1-tD2 [µmol/l]

93.913841

C_max_tD1-tD2_norm [mg/l]

1823712.8

C_max_tDlast-tEnd [µmol/l]

72.840813

C_max_tDLast-tEnd_norm [mg/l]

5657982.8

C_trough_tD2 [µmol/l]

62.880585

C_trough_tDlast [µmol/l]

57.953384

MRT [h]

96.416032

t_max [h]

192.75

t_max_tD1-tD2 [h]

0.75

t_max_tDlast-tEnd [h]

720.75

Half-Life [h]

66.702417

Half-Life_tDlast-tEnd [h]

77.49541

Table 15. Parameter output of the population simulation of caffeine

Sub-group analysis:

The preterm population was divided into subgroups based on neonatal body weight and Post Natal Age
(PNA). Three subgroups based on body weight (0.5Kg-1.0Kg, 1.0Kg-1.5Kg, >1.5Kg) and two subgroups
based on PNA (0-10 days and >10 days). The tables represent the output PK parameters of the subpopulations.

I. Based on Body Weight

Predicted peripheral venous blood-plasma concentrations of caffeine (Arithmetic mean)
Predicted peripheral venous blood-plasma concentrations of caffeine (Arithmetic standard deviation)

•

Observed concentrations

Fig 10. Time Vs Concentration profile for preterm population with body weight range 0.5 to 1.0 Kg

Predicted peripheral venous blood-plasma concentrations of caffeine (Arithmetic mean)
Predicted peripheral venous blood-plasma concentrations of caffeine (Arithmetic standard deviation)
•

Observed concentrations

Fig 11. Time Vs Concentration profile for preterm population with body weight range 1.0 to 1.5 Kg

Predicted peripheral venous blood-plasma concentrations of caffeine (Arithmetic mean)
Predicted peripheral venous blood-plasma concentrations of caffeine (Arithmetic standard deviation)

•

Observed concentrations

Fig 12. Time Vs Concentration profile for preterm population with body weight above 1.5Kg

PARAMETER

GROUP 1

GROUP 2

GROUP 3

AUC_inf_tD1 [µmol*min/l]

465013.44

431324.2

481387.4

AUC_inf_tD1_norm [µg*min/l]

9.03E+12

8.38E+12

9.35E+12

AUC_inf_tDLast [µmol*min/l]

482007.66

457738.9

557130.7

AUC_inf_tDLast_norm [µg*min/l]

3.744E+13

3.56E+13

4.33E+13

AUC_tD1-tD2 [µmol*min/l]

101948.83

103127

103568.8

AUC_tD1-tD2_norm [µg*min/l]

1.98E+12

2E+12

2.01E+12

AUC_tDlast-1_tDlast [µmol*min/l]

94410.422

91561.48

102695.6

AUC_tDlast-1_tDlast_norm [µg*min/l]

7.333E+12

7.11E+12

7.98E+12

C_max [µmol/l]

94.501282

94.79954

98.69127

C_max_tD1-tD2 [µmol/l]

93.913841

94.79954

95.08429

C_max_tD1-tD2_norm [mg/l]

1823712.8

1840912

1846442

C_max_tDlast-tEnd [µmol/l]

72.840813

70.85256

78.92624

C_max_tDLast-tEnd_norm [mg/l]

5657982.8

5503543

6130674

C_trough_tD2 [µmol/l]

62.880585

62.3846

63.89842

C_trough_tDlast [µmol/l]

57.953384

56.0673

63.60205

MRT [h]

96.416032

87.73719

98.67993

t_max [h]

192.75

0.75

216.75

t_max_tD1-tD2 [h]

0.75

0.75

0.75

t_max_tDlast-tEnd [h]

720.75

720.75

720.75

Half-Life [h]

66.702417

60.77594

68.30734

Half-Life_tDlast-tEnd [h]

77.49541

75.67403

82.73179

Table 16. PK-parameter output for the Body Weight subgroup analysis of caffeine

II. Based on PNA

Predicted peripheral venous blood-plasma concentrations of caffeine (Arithmetic mean)
Predicted peripheral venous blood-plasma concentrations of caffeine (Arithmetic standard deviation)
•

Observed concentrations

Fig 13. Time vs Conc profile for preterm population with postnatal age (PNA) range of 0 to 10 days

Predicted peripheral venous blood-plasma concentrations of caffeine (Arithmetic mean)
Predicted peripheral venous blood-plasma concentrations of caffeine (Arithmetic standard deviation)

•

Observed concentrations

Fig 14. Time vs Conc profile for preterm population with postnatal age (PNA) range of greater than 10
days

PARAMETER

GROUP 1

GROUP 2

AUC_inf_tD1 [µmol*min/l]

491035.0313

415170.6563

AUC_inf_tD1_norm [µg*min/l]

9.16866E+12

7.75211E+12

AUC_inf_tDLast [µmol*min/l]

574660.5

446638.8125

AUC_inf_tDLast_norm [µg*min/l]

4.16393E+13

3.2363E+13

AUC_tD1-tD2 [µmol*min/l]

107675.5859

103911.1484

AUC_tD1-tD2_norm [µg*min/l]

2.01053E+12

1.94024E+12

AUC_tDlast-1_tDlast [µmol*min/l]

105139.6875

93482.32813

AUC_tDlast-1_tDlast_norm [µg*min/l]

7.61831E+12

6.77363E+12

C_max [µmol/l]

107.3054962

95.71002197

C_max_tD1-tD2 [µmol/l]

98.02106476

95.71002197

C_max_tD1-tD2_norm [mg/l]

1830260.634

1787108.541

C_max_tDlast-tEnd [µmol/l]

80.44139862

73.33685303

C_max_tDLast-tEnd_norm [mg/l]

5828699.589

5313911.915

C_trough_tD2 [µmol/l]

66.05621338

62.54024506

C_trough_tDlast [µmol/l]

64.98568726

56.94951248

MRT [h]

96.79428711

83.0654541

t_max [h]

240.75

0.75

t_max_tD1-tD2 [h]

0.75

0.75

t_max_tDlast-tEnd [h]

768.75

768.75

Half-Life [h]

67.04505208

57.49594727

Half-Life_tDlast-tEnd [h]

83.71397298

71.82002767

Table 17. PK-parameter output for the PNA subgroup analysis of caffeine

4.1.4 Discussion

Bodyweight, postnatal age, postmenstrual age and gestational age are the major parameters concerning the
dosing in the neonatal population (Lawrence C. Ku et.al.). Pharmacokinetics of the drug are not only different
between neonates, older children and adults, but they also vary among neonates with different ranges of maturity.
As the age increases the renal and hepatic metabolism is very well developed leading to the changes in the
potency, efficacy and toxicity of the drug (Hong Lu, PhD et.al, Warner A.et.al.). Of these wide differences, body
weight and postnatal age are considered to be having a potential role in determining the safe dose in neonates as
they are directly related to the growth and development in the neonates (Loebstein R et.al).

Caffeine citrate which is used in the treatment of the apnea of prematurity is among the most frequently used
drug in the neonatal group (Hsieh E M et.al). The therapeutic range of caffeine in neonates is 5-25 mg/L and the
drug should measure >40mg/L to show the toxic levels (Johnson P J et.al). According to the current treatment
guidelines, the dose of caffeine is titrated according to the body weight of an infant to attain the therapeutic range
(Hey E, Ed et.al). The dosage regimen according to the guideline is 20mg/kg of the caffeine citrate as a loading
dose followed by 5-10 mg/kg of the maintenance dose (Caffeine Citrate label.).

The population model simulated is validated by the visual predictive curve comparing the predicted and observed
outcomes. The half-life and Cmax obtained are similar to the PBPK model of caffeine by Gary Ginsberg et.al
and is within the range of 42-103 hrs in neonates (Abdel-Hady H et.al). In the first few weeks of birth, caffeine
is mainly excreted by the kidneys due to the lack of hepatic enzymes which leads to decreased drug metabolism
which picks up as the age increases and the drug is cleared more rapidly (Abdel-Hady H et.al). This could
probably explain the drop in the Cmax as the treatment duration increases (Multi-dose study). In the simulation,
the AUC and Cmax in all the three groups based on the bodyweight are very close with minimal variance. This
can be inferred as the dose increased with respect to the bodyweight could effectively manage the increased
clearance due to the hepatic enzyme maturation.

The decrease in the Cmax with an increase in the age should be explained in the output. In the covariate analysis
of the population pharmacokinetic studies, the concentration of the caffeine is found to be affected only by the
bodyweight but there is evidence of the effect of the postnatal age.

CONCLUSION

From the aminophylline study, it can be concluded that dose adjustments are needed for aminophylline /
theophylline in the treatment of apnea of prematurity in neonates. With several instances of toxicity being
reported with aminophylline / theophylline (Tracey H Reilly, 2019) it is necessary to individualize the dose to
each individual. As stated earlier, PBPK modelling can be used to estimate pharmacokinetic (PK) parameters of
each individual which in turn helps in individualizing the dosage regimen.it was also found out that covariates
bodyweight and postnatal age are the two factors that influence the dosing regimens in these patients due to
increase in the maturation of enzymes with time. By developing a PBPK model from the data available, the
obtained pharmacokinetic parameters can be used to effectively calculate, adjust and administer the optimal dose
of aminophylline / theophylline in patients with apnea of prematurity. This helps in preventing toxic or subtherapeutic concentrations of the drug.

Caffeine study results suggest that the dosage regimen of caffeine citrate in the treatment of apnea in preterm
neonates is efficacious and results in appropriate plasma concentrations. Previous studies have suggested that
conventional plasma concentrations of caffeine can be obtained when dosed based on body weight and postnatal
age of neonates. Our study which was based on PBPK modelling of caffeine, using PK-Sim supports the above
study. It also provides an optimal dosing strategy to individualize the dose to each patient.
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APPENDIX

Appendix I – Part of aminophylline data
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Appendix II – Part of Caffeine data
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